Literature DB >> 12041507

Circulating immunoglobulin-bound transforming growth factor beta at a late tumour-bearing stage impairs antigen-specific responses of CD4+ T cells.

M Harada1, K Tatsugami, M Nomoto, K Nomoto.   

Abstract

In order to elucidate the mechanisms by which tumour-specific CD4+ T-cell responses are impaired during tumour development, an attempt was made to identify factors which impair CD4+ T-cell responses at a late tumour-bearing stage. Plasma from mice bearing B16 melanoma for 30 days (plasma d30) showed a more profound immunosuppressive effect on the in vitro proliferation of unrelated antigen-specific CD4+ T cells in the presence of both antigen and antigen-presenting cells (APC) than plasma from naïve mice. The level of plasma transforming growth factor (TGF)- was elevated in mice bearing B16 melanoma for 30 days compared with naïve mice, and the suppressive effect of plasma d30 was partially diminished by the neutralization of TGF-. Interestingly, immunoglobulin (IgG)-bound TGF-, but not IgG-unbound TGF-, in plasma d30 was suggested to be responsible for the immunosuppressive activity. In addition, no suppressive effect of plasma d30 was observed when antigen was added as a class II peptide, thus suggesting that the impaired proliferation of CD4+ T cells in the presence of plasma d30 was due to a dysfunction of antigen uptake/processing by APC. Furthermore, dissociation between IgG and TGF- resulted in a loss of the suppressive activity of plasma d30. Taken together, these results suggest that circulating IgG-bound TGF- is, at least in part, responsible for the impaired responses of CD4+ T cells at the late tumour-bearing stage by suppressing antigen uptake/ processing by APC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12041507      PMCID: PMC1906390          DOI: 10.1046/j.1365-2249.2002.01806.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state.

Authors:  T Tada; S Ohzeki; K Utsumi; H Takiuchi; M Muramatsu; X F Li; J Shimizu; H Fujiwara; T Hamaoka
Journal:  J Immunol       Date:  1991-02-01       Impact factor: 5.422

2.  Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma.

Authors:  F Kong; R L Jirtle; D H Huang; R W Clough; M S Anscher
Journal:  Cancer       Date:  1999-11-01       Impact factor: 6.860

3.  The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia.

Authors:  K R Schultz; J P Klarnet; R S Gieni; K T HayGlass; P D Greenberg
Journal:  Science       Date:  1990-08-24       Impact factor: 47.728

4.  Inhibition of human NK cell and LAK cell cytotoxicity and differentiation by PGE2.

Authors:  K H Leung
Journal:  Cell Immunol       Date:  1989-10-15       Impact factor: 4.868

5.  Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer.

Authors:  S M Gorsch; V A Memoli; T A Stukel; L I Gold; B A Arrick
Journal:  Cancer Res       Date:  1992-12-15       Impact factor: 12.701

6.  IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells.

Authors:  D F Fiorentino; A Zlotnik; P Vieira; T R Mosmann; M Howard; K W Moore; A O'Garra
Journal:  J Immunol       Date:  1991-05-15       Impact factor: 5.422

7.  Co-stimulation of T cell proliferation by transforming growth factor-beta 1.

Authors:  H M Lee; S Rich
Journal:  J Immunol       Date:  1991-08-15       Impact factor: 5.422

8.  A first or dominant immunization. I. Suppression of simultaneous cytolytic T cell responses to unrelated alloantigens.

Authors:  D A Rowley; R M Stach
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

Review 9.  Transforming growth factor-beta: recent progress and new challenges.

Authors:  M B Sporn; A B Roberts
Journal:  J Cell Biol       Date:  1992-12       Impact factor: 10.539

10.  A first or dominant immunization. II. Induced immunoglobulin carries transforming growth factor beta and suppresses cytolytic T cell responses to unrelated alloantigens.

Authors:  R M Stach; D A Rowley
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

View more
  1 in total

1.  Human immunophenotyping via low-variance, low-bias, interpretive regression modeling of small, wide data sets: Application to aging and immune response to influenza vaccination.

Authors:  Tyson H Holmes; Xiao-Song He
Journal:  J Immunol Methods       Date:  2016-05-16       Impact factor: 2.303

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.